<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04963816</url>
  </required_header>
  <id_info>
    <org_study_id>34737/6/21</org_study_id>
    <nct_id>NCT04963816</nct_id>
  </id_info>
  <brief_title>Pediatric Postoperative Analgesia With Quadratus Lumborum Block(QLB) And Dexamethasone As An Adjuvant To Bupivacaine.</brief_title>
  <acronym>QLB</acronym>
  <official_title>Pediatric Postoperative Analgesia With Quadratus Lumborum Block And Dexamethasone As An Adjuvant In Two Routes With Bupivacaine. Prospective Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studying the post-operative analgesic effect of dexamethasone as an adjuvant to bupivacaine&#xD;
      giving intravenously and locally with ultrasound guided quadratus lumborum block(QLB) in&#xD;
      pediatrics undergoing abdominal surgeries&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After obtaining written informed consent from parents or guardians of all patients, 90&#xD;
      patients (6-12 years old) scheduled for abdominal surgeries operations will be included.&#xD;
      Patients will be randomly allocated into three groups, 30 patients in each group.&#xD;
      Randomization will be based on computer-generated codes maintained in sequentially numbered&#xD;
      opaque envelopes.&#xD;
&#xD;
      Anesthetic Technique:&#xD;
&#xD;
      Anesthesia will be induced with Sevoflurane plus fentanyl (0.5µg/kg) and tracheal intubation&#xD;
      will be facilitated with Rocuronium (0.4 mg/kg). Anesthesia will be maintained with&#xD;
      Sevoflurane (will be adjusted according to A line autoregressive index (AAI)) and Rocuronium&#xD;
      (0.1 mg/kg/dose will be given on the basis of train-of-four neuromuscular monitoring). ECG,&#xD;
      noninvasive blood pressure, heart rate, temperature, oxygen saturation, and exhaled CO2 (end&#xD;
      tidal CO2) will be continuously monitored during the procedure.&#xD;
&#xD;
      • After induction of anesthesia and before skin incision, a QLB will be performed in all&#xD;
      patients in the three groups.&#xD;
&#xD;
      The procedure will be done under ultrasound guidance using curved array transducer 5-2MHz&#xD;
      (Sonosite ultrasound system). Echogenic needle, Sono Plex Stim cannula (PAJUNK) 22 gauge and&#xD;
      60 mm length will be used. With the patient in the supine position, the site of the&#xD;
      ultrasound and needle entry will be sterilized. The QLB block will be performed by anterior&#xD;
      approach. The linear probe will be attached in the area of the triangle of Petit in&#xD;
      transverse orientation in lateral abdomen in between the iliac crest and the costal margin,&#xD;
      near the posterior axillary line. The muscle planes will be identified until visualizing the&#xD;
      quadratus lumborum muscle, at the same plane as the psoas major muscle and the erector&#xD;
      spinae. The needle tip is placed at the anterolateral border of the QL at its junction of QL&#xD;
      with transversalis fascia outside the anterior layer of the thoracolumbar fascia (TLF) and&#xD;
      fascia transversalis, and the local anesthetic will be injected.&#xD;
&#xD;
      Anesthesia will be discontinued when the wound dressing applied, and muscle relaxant will be&#xD;
      reversed using (50ug/kg) of neostigmine and atropine (0.02mg/kg) and extubating of the&#xD;
      patient will be done. The patient will be transferred to the postoperative care unit (POCU).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">October 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative analgesia</measure>
    <time_frame>24 hours</time_frame>
    <description>using the Pediatric Objective Pain Scale (15), where each criterion scores 0 - 2 to give a total score 0 - 10, and a total score of less than 5 mean adequate analgesia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The duration of analgesia</measure>
    <time_frame>24 hours</time_frame>
    <description>the time starting from extubation until analgesia will be required as evidenced by a pain score &gt; 4.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The total amount of paracetamol doses</measure>
    <time_frame>24 hours</time_frame>
    <description>paracetamol doses (15 mg/kg per dose) as a rescue analgesic will be needed after the onset of pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative vomiting</measure>
    <time_frame>12 hours</time_frame>
    <description>vomiting and/or retching without expulsion of gastric content will be recorded by a nurse who will be blinded to study conditions. It will treated if vomiting occurred more than twice in 2 minutes with by granisetron</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">3</enrollment>
  <condition>Post Operative Pain</condition>
  <condition>Quadratus Lumborum Block</condition>
  <condition>Pediatric</condition>
  <condition>Abdominal Surgery</condition>
  <arm_group>
    <arm_group_label>Group A Quadratus Lumborum Block with dexamethasone IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>QLB with (0.5 mL/kg of bupivacaine 0.25%) and IV dexamethasone (0.1-0.3 mg/kg with a maximum dose 10 mg) added to 5 mL normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B Quadratus Lumborum Block with dexamethasone locally</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>QLB with (0.5 mL/kg of bupivacaine 0.25% plus dexamethasone 0.1 mg/kg), and IV 5 mL normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C Quadratus Lumborum Block with bupivacaine alone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive QLB (0.5 mL/kg of bupivacaine 0.25%) and IV 5 mL normal saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ultrasound guided quadratus lumborum block</intervention_name>
    <description>Ultrasound guided quadratus lumborum block will be done to all groups using curved array transducer 5_2 MHz with the patient in supine position and the block will be done by anterior approach</description>
    <arm_group_label>Group A Quadratus Lumborum Block with dexamethasone IV</arm_group_label>
    <arm_group_label>Group B Quadratus Lumborum Block with dexamethasone locally</arm_group_label>
    <arm_group_label>Group C Quadratus Lumborum Block with bupivacaine alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone Phosphate 4 MG/ML Injectable Solution intravenously</intervention_name>
    <description>Using dexamethasone as an adjuvant to bupivacaine in ultrasound guided quadratus lumborum block which will be given intravenously in group A</description>
    <arm_group_label>Group A Quadratus Lumborum Block with dexamethasone IV</arm_group_label>
    <other_name>Dexamethasone as an adjuvant intravenously</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine Injection</intervention_name>
    <description>Bupivacaine will be given to all groups locally with QLB</description>
    <arm_group_label>Group A Quadratus Lumborum Block with dexamethasone IV</arm_group_label>
    <arm_group_label>Group B Quadratus Lumborum Block with dexamethasone locally</arm_group_label>
    <arm_group_label>Group C Quadratus Lumborum Block with bupivacaine alone</arm_group_label>
    <other_name>Light marcaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone Phosphate 4 MG/ML Injectable Solution locally</intervention_name>
    <description>Using dexamethasone as an adjuvant to bupivacaine in ultrasound guided quadratus lumborum block which will be given locally in Group B</description>
    <arm_group_label>Group B Quadratus Lumborum Block with dexamethasone locally</arm_group_label>
    <other_name>Dexamethasone as an adjuvant locally</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pediatric patients(6-12 years)&#xD;
&#xD;
          -  ASA physical status I,II&#xD;
&#xD;
          -  Abdominal surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Parents refusal or legal guardian's refusal&#xD;
&#xD;
          -  Allergy to bupivacaine or dexamethasone&#xD;
&#xD;
          -  Contraindications to regional techniques&#xD;
&#xD;
          -  Failed QLB&#xD;
&#xD;
          -  Infection on site of procedure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AHMED A SHAMA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lecturer and consultant of anesthesia and surgical ICU in Tanta University and Faculty of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>SHERIF K ARAFA, MD</last_name>
    <role>Study Chair</role>
    <affiliation>ASSISTANT PROFESSOR of anesthesia and surgical ICU</affiliation>
  </overall_official>
  <overall_official>
    <last_name>AMIR A EL SAYED, MD</last_name>
    <role>Study Chair</role>
    <affiliation>ASSISTANT PROFESSOR of anesthesia and surgical ICU</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AHMED A SHAMA, MD</last_name>
    <phone>00966580925443</phone>
    <email>ahmed.shama@med.tanta.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tanta University</name>
      <address>
        <city>Tanta</city>
        <state>Algharbia</state>
        <zip>0000</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AHMED A SHAMA, MD</last_name>
      <phone>00966580925443</phone>
      <email>ahmed.shama@med.tanta.edu.ed</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 23, 2021</study_first_submitted>
  <study_first_submitted_qc>July 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>AHMED ABDELAZIZ SHAMA</investigator_full_name>
    <investigator_title>Lecturer and consultant of anesthesia and surgical ICU</investigator_title>
  </responsible_party>
  <keyword>Quadratus lumborum block in pediatrics</keyword>
  <keyword>Dexamethasone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

